PsiQuantum has announced a collaborative research agreement with National Cancer Center Japan, one of Japan’s leading institutions for cancer research and treatment. The partnership aims to explore and develop utility-scale quantum computing applications for oncology and broader healthcare use cases.
The collaboration highlights the growing potential of quantum computing in healthcare, particularly in areas such as pharmaceutical research and development, healthcare resource optimization and improved patient outcomes in cancer treatment.
Advancing Quantum Algorithms for Healthcare Innovation
Through the agreement, PsiQuantum will work with the National Cancer Center Japan to advance the development of fault-tolerant quantum algorithms and collaborate with the institution as well as leading pharmaceutical companies in Japan. The focus will be on building clinically relevant quantum computing applications capable of addressing complex challenges in cancer research and drug development.
As part of the initiative, the teams will leverage PsiQuantum’s software platform Construct, a secure end-to-end environment designed for designing, analyzing and optimizing algorithms for fault-tolerant quantum computing systems.
Also Read: Eaton Completes Acquisition of Boyd Thermal for Data Centers
“PsiQuantum is proud to work alongside the National Cancer Center Japan as we explore what utility-scale quantum computing will be able to deliver in designing new treatments for the benefit of researchers and patients,” said Sam Pallister, PsiQuantum’s Vice President for Quantum Applications. “Once deployed, utility-scale quantum computers will accelerate research and development that transforms how we develop new medicines-and partnerships like these are critical for making sure providers are equipped to take full advantage of this technology.”
“We are thrilled to partner with PsiQuantum on leveraging quantum computing technology to address some of the most pressing challenges in healthcare,” said Takayuki Yoshino, Director for the Department of Global Oncology at the National Cancer Center Hospital East in Kashiwa, Japan. “Together, our teams are poised to conduct innovative research and unlock new solutions at the intersection of pharmaceuticals, biotechnology, and quantum computing.”
Revolutionizing Drug Discovery with Quantum Computing
The process of creating new pharmaceutical products continues to be a resource-intensive and costly endeavor. In addition, traditional computational techniques have difficulty simulating molecular systems at the necessary degree of precision to improve the process of drug discovery and development.
Quantum computers have the potential to revolutionize the process of drug discovery. By providing the ability to simulate molecular systems at a chemically precise level, quantum computers have the potential to greatly improve the process of drug discovery. This will not only reduce the cost of research and development but also decrease the time to market for new pharmaceutical products.
Through this collaboration, PsiQuantum and the National Cancer Center Japan seek to explore the potential for quantum-powered healthcare innovation to transform the field of oncology research and drive breakthroughs in new therapies.
